NGÓéÀÖÏàÐÅÆ·ÅÆÁ¦Á¿¹ÙÍø

ͼƬÃû³Æ

ÐÂÎÅ×ÊѶ

ÆƾÖÌÇÄò²¡Éö²¡£¡£¡£¡£¡£¡£¡£ ¡£¡NGÓéÀÖÏàÐÅÆ·ÅÆÁ¦Á¿¹ÙÍøMCR»·ëÄÁÆ·¨ÁÙ´²Ç°ÁÆЧÏÔÖø

ÈÕÆÚ£º

2026Äê06ÔÂ15ÈÕ 15:43

ÌÇÄò²¡Éö²¡ÊÇʲô£¿ £¿£¿£¿£¿£¿£¿£¿

 

ÌÇÄò²¡Éö²¡£¡£¡£¡£¡£¡£¡£ ¡£¨diabetic nephropathy £¬£¬£¬£¬£¬DN£©ÊÇÌÇÄò²¡×îÑÏÖغÍ×î³£¼ûµÄ΢Ѫ¹Ü²¢·¢Ö¢Ö®Ò» £¬£¬£¬£¬£¬ÔÚҽѧÉÏÒ²³ÆΪÌÇÄò²¡ÉöСÇòÓ²»¯Ö¢¡£¡£¡£¡£¡£¡£¡£ ¡£ËüÊÇÂýÐÔÉöÔಡ£¡£¡£¡£¡£¡£¡£ ¡£¨chronic kidney disease £¬£¬£¬£¬£¬CKD£©ºÍÖÕÄ©ÆÚÉöÔಡ£¡£¡£¡£¡£¡£¡£ ¡£¨end stage renal disease, ESRD£©µÄÖ÷Òª²¡Òò1¡£¡£¡£¡£¡£¡£¡£ ¡£ÏÖÔÚ £¬£¬£¬£¬£¬ÔÚÎÒ¹úÒÔÖÂÈ«ÇòÌÇÄò²¡Éö²¡·¢²¡Âʾù³ÊÉÏÉýÇ÷ÊÆ¡£¡£¡£¡£¡£¡£¡£ ¡£

ÌÇÄò²¡Éö²¡ÊÇÓÉÓÚºã¾Ã¸ßѪÌÇ״̬µ¼ÖÂÉöÔà½á¹¹ºÍ¹¦Ð§Öð½¥ÊÜËðµÄ²¡ÀíÀú³Ì¡£¡£¡£¡£¡£¡£¡£ ¡£»£»£»£»£»¼Õß»úÌå±£´æ¼«ÆäÖØ´óµÄ´úлÔÓÂÒ £¬£¬£¬£¬£¬Ò»µ©Éú³¤µ½ÖÕÄ©½×¶Î £¬£¬£¬£¬£¬ÍùÍù±ÈÆäËûÉöÔ༲²¡ÖÎÁÆÔ½·¢¼¬ÊÖ¡£¡£¡£¡£¡£¡£¡£ ¡£ÌÇÄò²¡Éö²¡ÔçÆÚÌØÕ÷ÐԸıä°üÀ¨ÉöСÇòÂ˹ýÂÊÔö¸ß¡¢ÉöÌå»ýÔö´ó £¬£¬£¬£¬£¬Ëæºó·ºÆð΢Á¿°×ÂÑ°×Äò £¬£¬£¬£¬£¬¼Ì¶øÉú³¤ÎªÁÙ´²ÂÑ°×Äò¡¢ÉöÏËά»¯ £¬£¬£¬£¬£¬×îÖÕµ¼ÖÂÉö¹¦Ð§¾ÙÐÐÐÔϽµ £¬£¬£¬£¬£¬Ö±ÖÁÖÕÄ©ÆÚÉöË¥½ß1¡£¡£¡£¡£¡£¡£¡£ ¡£

£¨Í¼Æ¬ÈªÔ´£ºhttps://www.hjtdsm.com/yiyong/dn£©

 

¼òÎöÏÖÓÐÁÆ·¨ £¬£¬£¬£¬£¬¿ÉÒÔ·¢Ã÷ £¬£¬£¬£¬£¬È±·¦Äܹ»Ö±½Ó¡¢Ç¿Á¦×è¶ÏÉöÔàÄÚÔÚÑ×Ö¢ºÍÏËά»¯Àú³ÌµÄ¶à°ÐµãÒ©Îï £¬£¬£¬£¬£¬ÊÇÄ¿½ñÌÇÄò²¡Éö²¡ÖÎÁÆÁìÓò×îÖ÷ÒªµÄÁÙ´²Î´Öª×ãÐèÇ󡣡£¡£¡£¡£¡£¡£ ¡£

NGÓéÀÖÏàÐÅÆ·ÅÆÁ¦Á¿¹ÙÍø£¨ÒÔϼò³Æ“NGÓéÀÖÏàÐÅÆ·ÅÆÁ¦Á¿¹ÙÍø”£©×ÔÖ÷Ñз¢µÄС·Ö×Ó»·ëÄ£¨MCR¶àëÄ£©ÔÚ×Ô¾õÐÍÌÇÄò²¡Éö²¡Ä£×ÓСÊó——db/dbСÊóÉÏÈ¡µÃÁËÏÔÖøÁÆЧ £¬£¬£¬£¬£¬Í¨¹ý¶à°ÐµãЭͬÔöЧ £¬£¬£¬£¬£¬ÓÐÍû´øÀ´DNµÄÁÙ´²ÐÂÑ¡Ôñ£¡

 

MCR»·ëÄÁÆЧÏÔÖø

 

db/dbСÊóÊÇÑо¿ÔçÆÚÌÇÄò²¡Éö²¡²¡±äµÄ³£ÓÃÄ£×Ó £¬£¬£¬£¬£¬ÆäÓÉÓÚ»ùÒòÍ»±äµ¼ÖÂÊÝËØÊÜÌ幦ЧȱÏÝ £¬£¬£¬£¬£¬³ýÁ˻᷺Æð·ÊÅÖ¡¢¸ßѪÌǵÈÖ¢×´ £¬£¬£¬£¬£¬¸ÃÄ£×ÓСÊóͨ³£»£»£»£»£»¹ÔÚÉúÃüÔçÆÚÌåÏÖ³öÏÔ×ŵÄÉöСÇòËðÉË£¨·Ê´ó¡¢Ï¸°ûÔö¶àºÍÉöСÇòÓ²»¯£© £¬£¬£¬£¬£¬Ëæ×ÅÄêËêµÄÔöÌí¶ø¼ÓÖØ £¬£¬£¬£¬£¬»¹ÌåÏÖ³öÖеÈˮƽµÄÂÑ°×Äò¡£¡£¡£¡£¡£¡£¡£ ¡£

ÊÔÑéЧ¹ûÏÔʾ £¬£¬£¬£¬£¬¾­ÓÉΪÆÚ8ÖܵÄÖÎÁÆ £¬£¬£¬£¬£¬Óë¿Õȱ±ÈÕÕ×édb/dbСÊóÏà±È £¬£¬£¬£¬£¬MCR»·ëĸ߼ÁÁ¿×éСÊóµÄÌÇÉöÏà¹ØÖ¸±ê¾ùÓÐÏÔ×ŵĸÄÉÆ£º

1¡¢ ¶àÌǺÍÌÇÂÑ°×ˮƽ£ºÏÔÖø½µµÍ×éÖ¯ÖжàÌǺÍÌÇÂÑ°×ˮƽ£»£»£»£»£»ÓëÄ£×Ó×éÏà±ÈϽµ·ù¶ÈÔ¼2/3 £¬£¬£¬£¬£¬ÓëGLP-1¶àëÄ×éÁÆЧÏ൱£»£»£»£»£»

2¡¢ ½ºÔ­ÂÑ°×ˮƽ£º´ó·ù¶È½µµÍ½ºÔ­ÂÑ°×ˮƽ£¨Ô¼2/3£© £¬£¬£¬£¬£¬ïÔÌ­½ºÔ­³Á»ý £¬£¬£¬£¬£¬ÏÔÖø¸ÄÉÆÉöÔàÏËά»¯Ë®Æ½ £¬£¬£¬£¬£¬ÓëGLP-1¶àëÄ×éÁÆЧÏ൱£»£»£»£»£»

3¡¢ ÄòÂÑ°×ˮƽ£ºÖÎÁÆ4Öܽ«ÄòÂÑ°×ˮƽ´Ó»ùÏß½µÖÁÒ»°ë¡£¡£¡£¡£¡£¡£¡£ ¡£

 

ͼ1. db/dbСÊóÉöÔಡ±äͼ

G1¿µ½¡±ÈÕÕ×é/G2Ä£×Ó×é/G3»·ëĵͼÁÁ¿×é/ G4»·ëĸ߼ÁÁ¿×é/G5 GLP-1¶àëÄ×é

 

MCR»·ëÄ£º¶à°ÐµãЭͬÔöЧ

 

MCR»·ëÄÔÚÌÇÄò²¡Éö²¡ÖÐÌåÏÖ³öµÄ׿ԽÁÆЧ £¬£¬£¬£¬£¬Ô´ÓÚÆä×÷ΪһÖÖЭͬÐÔË«ÊÜÌ弤¶¯¼ÁµÄÆæÒìÉè¼Æ¡£¡£¡£¡£¡£¡£¡£ ¡£¸Ã·Ö×ÓʹÓÃÆä¹¹ÏóÔ¼ÊøµÄ»·ëĽṹ £¬£¬£¬£¬£¬ÊµÏÖÁ˶ԺÚƤÖÊËØÊÜÌåÑÇÐÍMC1RºÍMC4RµÄ¸ßÇ׺ÍÁ¦¼°Ñ¡ÔñÐÔ¹²¼¤»î¡£¡£¡£¡£¡£¡£¡£ ¡£

ÕâÖÖË«ÖØ°ÐÏò×÷ÓÃÒý·¢ÁËÏÔÖøµÄЭͬÔöЧЧӦ £¬£¬£¬£¬£¬ÅäÏàÖúÓÃÓÚÌÇÄò²¡Éö²¡µÄ½¹µã²¡Àí»·½Ú £¬£¬£¬£¬£¬×îÖÕµ¼ÖÂÂÑ°×Äò¼õÇá¡¢×ãϸ°û±£»£»£»£»£»¤¼°ÉöСÇòÂ˹ý¹¦Ð§¸ÄÉƵȶàά¶È²¡ÀíÖ¸±êµÄÏÔÖøÄæת £¬£¬£¬£¬£¬Õ¹ÏÖÁ˶à°Ðµã¸ÉÔ¤Õ½ÂÔÔÚÖØ´ó´úлÐÔ¼²²¡ÖÎÁÆÖеÄÍ»³öÓÅÊÆ¡£¡£¡£¡£¡£¡£¡£ ¡£

¼¤»îMC1R£ºÃâÒßµ÷Àí¿¹Ñ×+ÒÖÖÆÏËά»¯Àú³Ì+Ö±½Ó±£»£»£»£»£»¤×ãϸ°û

MC1RÖ÷Òª±£´æÓÚƤ·ôÉ«ËØϸ°û¡¢ÃâÒßϸ°ûºÍÉöÔàϸ°û£¨°üÀ¨×ãϸ°ûºÍϵĤϸ°û£©¡£¡£¡£¡£¡£¡£¡£ ¡£Í¨¹ý¼¤»îMC1R £¬£¬£¬£¬£¬ÏÔÖøÒÖÖÆNF-κBµÄ»î»¯ £¬£¬£¬£¬£¬ïÔ̭һϵÁдÙÑ×ϸ°ûÒò×Ó£¨TNF-α¡¢IL-6µÈ£©µÄ±¬·¢2 3£»£»£»£»£»Í¬Ê±Ôö½ø¿¹Ñ×Òò×Ó£¨ÈçIL-10£©µÄÊÍ·Å2 3 £¬£¬£¬£¬£¬µ÷ÀíÃâÒßϸ°û £¬£¬£¬£¬£¬¸ÄÉÆÌåÄÚÑ×֢΢ÇéÐÎ £¬£¬£¬£¬£¬Å¤×ªÉöÔà´ÙÑ×״̬¡£¡£¡£¡£¡£¡£¡£ ¡£

ÉöÔàÏËά»¯£¨Ó²»¯£©Êǵ¼Ö¹¦Ð§ËðʧµÄ×îºóͨ·¡£¡£¡£¡£¡£¡£¡£ ¡£ÓÐÑо¿Åú×¢ £¬£¬£¬£¬£¬ºÚƤÖÊËؼ¤¶¯¼Á±»Ö¤Êµ¿ÉÒÔÞ׿¹´ÙÏËά»¯Òò×Ó£¨ÈçTGF-⣩ £¬£¬£¬£¬£¬´Ó¶øïÔÌ­½ºÔ­ÂÑ°×µÈϸ°ûÍâ»ùÖÊµÄºÏ³É £¬£¬£¬£¬£¬ÑÓ»ºÉöСÇòÓ²»¯ºÍ¼äÖÊÏËά»¯µÄÀú³Ì4¡£¡£¡£¡£¡£¡£¡£ ¡£

×ãϸ°ûÊÇ×é³ÉÉöÔàÂ˹ýÆÁÕϵÄÒªº¦Ï¸°û £¬£¬£¬£¬£¬ÆäËðÉ˺ÍÍÑÂäÊÇÂÑ°×ÄòµÄÖ÷ÒªÔµ¹ÊÔ­ÓÉ¡£¡£¡£¡£¡£¡£¡£ ¡£Ò»Ð©Ñо¿Ö¸³ö £¬£¬£¬£¬£¬ºÚƤÖÊËؼ¤¶¯¼ÁÄÜͨ¹ýÖ±½Ó×÷ÓÃÓÚ×ãϸ°ûÉϵÄÊÜÌ壨ÈçMC1R£© £¬£¬£¬£¬£¬ÎȹÌÆäϸ°û¹Ç¼Ü £¬£¬£¬£¬£¬ÒÖÖƵòÍö £¬£¬£¬£¬£¬´Ó¶ø´Ó½á¹¹ÉÏά»¤Â˹ý¹¦Ð§µÄÍêÕûÐÔ £¬£¬£¬£¬£¬ïÔÌ­ÂÑ°×Äò5 6¡£¡£¡£¡£¡£¡£¡£ ¡£

 

ͼ2. MCRÔÚÉöÔàϸ°ûÖеÄÂþÑÜ5

 

¼¤»îMC4R£º¸ÄÉÆÒȵºËضԿ¹ºÍ´úл

 

MC4RÖ÷Òª±£´æÓÚÖÐÊàÉñ¾­ÏµÍ³ £¬£¬£¬£¬£¬¼ÓÈëµ÷ÀíÄÜÁ¿Æ½ºâºÍʳÓû¡£¡£¡£¡£¡£¡£¡£ ¡£Í¨¹ý¼¤»îMC4R £¬£¬£¬£¬£¬¸ÄÉÆÈ«ÉíÒȵºËØÃô¸ÐÐÔºÍÆÏÌÑÌÇ´úл £¬£¬£¬£¬£¬ÓÐÀûÓÚ´ÓȪԴÉÏÖÎÁÆÌÇÄò²¡Éö²¡——ÌÇÄò²¡¡£¡£¡£¡£¡£¡£¡£ ¡£

 

MCR»·ëÄ£º¶à¼²²¡ÁìÓòDZÔÚÓ¦ÓÿÉÄÜÐÔ

 

Õ¹ÍûδÀ´ £¬£¬£¬£¬£¬NGÓéÀÖÏàÐÅÆ·ÅÆÁ¦Á¿¹ÙÍø½«ÒÔMCR»·ëÄÔÚ¼õÖØ´úлÁìÓòÈ¡µÃµÄÍ»ÆÆΪ»ùʯ £¬£¬£¬£¬£¬ÒÀ¸½Æä×÷ÓûúÖƵĽ¹µãÓÅÊÆ £¬£¬£¬£¬£¬Æð¾¢ÍØÕ¹ÖÐÊàÉñ¾­ÏµÍ³£¨CNS£©¼°×ÔÌåÃâÒߣ¨×ÔÃ⣩µÈDZÁ¦ÖØ´óµÄÐÂ˳Ӧ֢ÁìÓò¡£¡£¡£¡£¡£¡£¡£ ¡£

 

Êг¡Ô¶¾°ÓëÕ½ÂԽṹ

 

È«ÇòÌÇÄò²¡Éö²¡ÖÎÁÆÒ©ÎïÊг¡Õý´¦ÓÚ¿ìËÙÔöÌí½×¶Î £¬£¬£¬£¬£¬Ô¼30%-40%µÄÌÇÄò²¡»¼Õß»áÉú³¤ÎªÌÇÄò²¡Éö²¡ £¬£¬£¬£¬£¬»¼Õß»ùÊýÖش󡣡£¡£¡£¡£¡£¡£ ¡£2024ÄêÈ«ÇòDNÒ©ÎïÊг¡¹æÄ£ÒÑÍ»ÆÆ120ÒÚÃÀÔª £¬£¬£¬£¬£¬Ô¤¼Æ2030Ä꽫Áè¼Ý300ÒÚÃÀÔª £¬£¬£¬£¬£¬Ä긴ºÏÔöÌíÂÊ´ï12.5%7¡£¡£¡£¡£¡£¡£¡£ ¡£Öйú×÷ΪȫÇòÌÇÄò²¡»¼Õß×î¶àµÄ¹ú¼Ò £¬£¬£¬£¬£¬ÕïÁÆÂʵÄÒ»Á¬ÌáÉýʹÆä³ÉΪ×î¾ßÔöÌí»îÁ¦µÄÊг¡Ö®Ò»¡£¡£¡£¡£¡£¡£¡£ ¡£

Ö»¹ÜÏÖÓбê×¼ÁÆ·¨Ò»Ö±½ø»¯ £¬£¬£¬£¬£¬µ«ÉÐÎÞÄܹ»ÄæתÏËά»¯Àú³ÌµÄÌØÒìÐÔÒ©Îï¡£¡£¡£¡£¡£¡£¡£ ¡£MCR»·ëÄ´Ó¿¹Ñס¢¿¹ÏËά»¯¡¢´úлµ÷ÀíÈý´ó½¹µã»·½Úͬʱ½éÈë £¬£¬£¬£¬£¬ÓëÏÖÓÐÁÆ·¨ÐγÉÓÅÒ컥²¹ £¬£¬£¬£¬£¬ÓÈÆäÔÚ¿¹ÏËά»¯·½Ãæ¾ß±¸ÆæÒì²î±ð»¯ÓÅÊÆ¡£¡£¡£¡£¡£¡£¡£ ¡£

ÏÖÔÚ £¬£¬£¬£¬£¬¹«Ë¾Ñз¢¹ÜÏßÕýÎȲ½Íƽø £¬£¬£¬£¬£¬ºóÐø½«Öص㿪չϵͳµÄÁÙ´²Ç°Ò©Ð§Ó붾ÀíѧÑо¿ £¬£¬£¬£¬£¬Ïà¹Ø½¹µã»¯ºÏÎïÒÑ»ñµÃרÀûÊÚȨ £¬£¬£¬£¬£¬¹¹½¨Á˼áʵµÄÊÖÒÕ±ÚÀÝ¡£¡£¡£¡£¡£¡£¡£ ¡£ÔÚ´ËרÀû¼Ó³ÖÏ £¬£¬£¬£¬£¬NGÓéÀÖÏàÐÅÆ·ÅÆÁ¦Á¿¹ÙÍø½«È«Á¦¼ÓËÙÕâÒ»²î±ð»¯¶àëÄÐÂÒ©µÄÑз¢Àú³Ì £¬£¬£¬£¬£¬Ö¾ÔÚÔçÈÕ½«ÆäÍÆÏòÁÙ´² £¬£¬£¬£¬£¬Ô츣ȫÇò»¼Õß £¬£¬£¬£¬£¬Í¬Ê±ÇÀÕ¼ÕâǧÒÚÀ¶º£Êг¡µÄÕ½ÂԸߵء£¡£¡£¡£¡£¡£¡£ ¡£

 

 

×ÊÁÏȪԴ

1.Öйú¹«ÖÚ¿µ½¡Íø£¨2014£© £¬£¬£¬£¬£¬¾ÍÕïÖ¸ÄÏ ³£¼û¼²²¡ ÌÇÄò²¡Éö²¡.http://www.chealth.org.cn/mon/diseases/article/MA144004836.html

2. Wang, W., Guo, D. Y., Lin, Y. J., & Tao, Y. X. (2019). Melanocortin Regulation of Inflammation. Frontiers in endocrinology, 10, 683. https://doi.org/10.3389/fendo.2019.00683

3. Ahmed, T. J., Montero-Melendez, T., Perretti, M., & Pitzalis, C. (2013). Curbing Inflammation through Endogenous Pathways: Focus on Melanocortin Peptides. International journal of inflammation, 2013, 985815. https://doi.org/10.1155/2013/985815

4. ÕŽõ.ºÚƤÖÊËضԾÖÔî½Ú¶ÎÐÔÉöСÇòÓ²»¯Ö¢µÄÖÎÁÆ×÷Óü°»úÖÆÑо¿[D].Ö£ÖÝ´óѧ,2022.DOI:"". http://www.tzsti.com:90/D/Thesis_Y3990408.aspx

5. Chang, M., Chen, B., Shaffner, J., Dworkin, L. D., & Gong, R. (2021). Melanocortin System in Kidney Homeostasis and Disease: Novel Therapeutic Opportunities. Frontiers in physiology, 12, 651236. https://doi.org/10.3389/fphys.2021.651236

6. Luipa Khandker, PhD; Priyanka Dhingra, PhD; John H. Dodd, PhD; Carl Spana, PhD; Paul S. Kayne, PhD. (2023). Melanocortin 1 Receptor (MC1R) Agonist PL8177 Protects Against Podocyte Loss in a Streptozotocin-Induced <br/>Rat Model of Diabetic Nephropathy. 14th Biennial International Podocyte Conference Philadelphia, PA. 2023. https://palatin.com/wp-content/uploads/2023/05/PAL-G23PL8.3015-IPD-2023-Khandker-PL8177-Protects-Against-Podocyte-Loss-Poster-0518-2-OK-TO-PRINT.pdf

7. 2025ÖÁ2030ÌÇÄò²¡Éö²¡ÐÐÒµÔËӪ̬ÊÆÓëͶ×ÊÔ¶¾°ÊÓ²ìÑо¿±¨¸æ.https://max.book118.com/html/2025/1022/8123135105010001.shtm

Ïà¹ØÍƼö

¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿